Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

(2011) K. Fizazi et al.   EUROPEAN JOURNAL OF CANCER

The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study

(2011) Jayaprakash Karkera et al.   PROSTATE

Recruitment of Myeloid but not Endothelial Precursor Cells Facilitates Tumor Regrowth after Local Irradiation

(2010) S. V. Kozin et al.   CANCER RESEARCH

Targeting immune suppressing myeloid-derived suppressor cells in oncology

(2010) Johnny Kao et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Significance of Interleukin-6 Signaling in the Resistance of Pharyngeal Cancer to Irradiation and the Epidermal Growth Factor Receptor Inhibitor

(2010) Chih-Cheng Chen et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Role of DNA methyltransferase 1 in hormone-resistant prostate cancer

(2010) Miao-Fen Chen et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment

(2010) G.-O. Ahn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor

(2008) Kamilla Malinowska et al.   ENDOCRINE-RELATED CANCER